Tags

Type your tag names separated by a space and hit enter

Immune-mediated hepatitis induced by therapy with Alemtuzumab in a patient with Multiple Sclerosis.
Hepatology. 2020 Jun 24 [Online ahead of print]Hep

Abstract

Increased use of novel immunomodulatory agents has led to emerging forms of drug-induced liver injury. Alemtuzumab is a recombinant, humanized monoclonal antibody against CD52, which is present on T cells, B cells, monocytes and natural killer cells. A single dose results in a depletion of the entire lymphocyte population followed by varied kinetics in the recovery of each cell type. Alemtuzumab has been approved as an immune reconstitution therapy in relapsing and remitting multiple sclerosis (RRMS). Since its approval, cases of acute hepatitis have been documented but reports of delayed-onset immune-mediated hepatitis with recurrent episodes of liver failure following treatment with alemtuzumab have not been published.

Authors+Show Affiliations

Medizinische Klinik B für Gastroenterologie und Hepatologie, Universitätsklinikum Münster, Germany, Munster.Medizinische Klinik B für Gastroenterologie und Hepatologie, Universitätsklinikum Münster, Germany, Munster.Medizinische Klinik B für Gastroenterologie und Hepatologie, Universitätsklinikum Münster, Germany, Munster.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32583445

Citation

Bolte, Fabian J., et al. "Immune-mediated Hepatitis Induced By Therapy With Alemtuzumab in a Patient With Multiple Sclerosis." Hepatology (Baltimore, Md.), 2020.
Bolte FJ, Schmidt HH, Schlevogt B. Immune-mediated hepatitis induced by therapy with Alemtuzumab in a patient with Multiple Sclerosis. Hepatology. 2020.
Bolte, F. J., Schmidt, H. H., & Schlevogt, B. (2020). Immune-mediated hepatitis induced by therapy with Alemtuzumab in a patient with Multiple Sclerosis. Hepatology (Baltimore, Md.). https://doi.org/10.1002/hep.31435
Bolte FJ, Schmidt HH, Schlevogt B. Immune-mediated Hepatitis Induced By Therapy With Alemtuzumab in a Patient With Multiple Sclerosis. Hepatology. 2020 Jun 24; PubMed PMID: 32583445.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Immune-mediated hepatitis induced by therapy with Alemtuzumab in a patient with Multiple Sclerosis. AU - Bolte,Fabian J, AU - Schmidt,Hartmut H-J, AU - Schlevogt,Bernhard, Y1 - 2020/06/24/ PY - 2020/6/26/entrez JF - Hepatology (Baltimore, Md.) JO - Hepatology N2 - Increased use of novel immunomodulatory agents has led to emerging forms of drug-induced liver injury. Alemtuzumab is a recombinant, humanized monoclonal antibody against CD52, which is present on T cells, B cells, monocytes and natural killer cells. A single dose results in a depletion of the entire lymphocyte population followed by varied kinetics in the recovery of each cell type. Alemtuzumab has been approved as an immune reconstitution therapy in relapsing and remitting multiple sclerosis (RRMS). Since its approval, cases of acute hepatitis have been documented but reports of delayed-onset immune-mediated hepatitis with recurrent episodes of liver failure following treatment with alemtuzumab have not been published. SN - 1527-3350 UR - https://www.unboundmedicine.com/medline/citation/32583445/Immune-mediated_hepatitis_induced_by_therapy_with_Alemtuzumab_in_a_patient_with_Multiple_Sclerosis L2 - https://doi.org/10.1002/hep.31435 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.